SCHEMBL25979227

SCHEMBL25979227

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4c(c3)oc3ccc(-c5cccc(N(c6ccccc6)c6cccc7ccccc67)c5)cc34)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.34
CHEK2 O96017 1/20 0.34
MAPT P10636 4/20 0.33
TSHR P16473 4/20 0.33
PLA2G2A P14555 3/20 0.33
PLA2G4A P47712 3/20 0.33
KDM4E B2RXH2 3/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
ALDH1A1 P00352 2/20 0.33
PLA2G10 O15496 1/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
MMP12 P39900 2/20 0.33
CYP1A1 P04798 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP1B1 Q16678 1/20 0.32
MAPK1 P28482 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25978939 0.96 PLA2G2A (0.34) HCRTR1CHEK2MAPTTSHRPLA2G2A
SCHEMBL25979761 0.96 CYP1A2 (0.34) HCRTR1MAPTTSHRKDM4EHPGD
SCHEMBL25978664 0.94 MAPT (0.34) MAPTTSHRKDM4EHPGDHSD17B10
SCHEMBL26779099 0.94 PLA2G2A (0.35) HCRTR1CHEK2MAPTTSHRPLA2G2A
SCHEMBL25979001 0.93 PLA2G2A (0.35) HCRTR1CHEK2MAPTTSHRPLA2G2A
SCHEMBL25978969 0.92 PLA2G2A (0.35) HCRTR1CHEK2MAPTTSHRPLA2G2A
SCHEMBL26779035 0.92 MAPT (0.34) MAPTTSHRPLA2G2APLA2G4AKDM4E
SCHEMBL25979642 0.91 ALDH1A1 (0.34) HCRTR1MAPTTSHRKDM4EHPGD
SCHEMBL25979466 0.91 MAPT (0.34) MAPTTSHRKDM4EHPGDHSD17B10
SCHEMBL25979153 0.90 PLA2G2A (0.37) HCRTR1CHEK2MAPTPLA2G2APLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 HCRTR1 549/4885CHEK2 2043/4885MAPT 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.